Evidence map›Paper›PMID 29157955›Full record

ArticleExperimental and molecular pathology2017

Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.

Leslie C Sherwood, Farrukh Aqil, Manicka V Vadhanam, Jeyaprakash Jeyabalan, Radha Munagala, David Hoetker, Sanjay Srivastava, Inder P Singh, Scott Cambron, Martin O'Toole and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and molecular pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Leslie C SherwoodResearch Resources Facilities, University of Louisville, Louisville, KY 40202, United States. Electronic address: lcsher01@louisville.edu.
Farrukh AqilDepartment of Medicine, University of Louisville, Louisville, KY 40202, United States; James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, United States.
Manicka V VadhanamJames Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, United States.
Jeyaprakash JeyabalanJames Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, United States.
Radha MunagalaDepartment of Medicine, University of Louisville, Louisville, KY 40202, United States; James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, United States.
David HoetkerDivision of Cardiovascular Medicine, University of Louisville, Louisville, KY 40202, United States.
Sanjay SrivastavaDepartment of Medicine, University of Louisville, Louisville, KY 40202, United States; Division of Cardiovascular Medicine, University of Louisville, Louisville, KY 40202, United States.
Inder P SinghNational Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India.
Scott CambronDepartment of Bioengineering, University of Louisville, Louisville, KY 40202, United States.
Martin O'TooleDepartment of Bioengineering, University of Louisville, Louisville, KY 40202, United States.
Wendy Spencer3P Biotechnologies, Inc., Louisville, KY 40202, United States.
Lynn P ParkerNorton Cancer Institute, Louisville, KY 40202, United States.
Ramesh C GuptaJames Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, United States; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, United States. Electronic address: rcgupta@louisville.edu.
University of Louisville · USNational Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · INNorton Healthcare · USOPX Biotechnologies (United States) · US

Funding

Sustained, target delivery for treatment of cervical pathologiesR43CA162417 · NCI · 3P BIOTECHNOLOGIES, INC. · PI GUPTA, RAMESH C, SPENCER, WENDY A · 2012 to 2013
$298k
NCI NIH HHS R43 CA162417
6 · The paper itself

Abstract

Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN

Indexed as

Drug Delivery SystemsAnimalsDisease Models, AnimalFemaleGoatsHumansPapillomaviridaePapillomavirus InfectionsPregnancyUterine Cervical DysplasiaWithanolideswithaferin AWithanolidesCervical cancerCervical dysplasiaCervical polymeric implantGoat modelLocal drug delivery

Identifiers

PMID29157955
PMCPMC5746057
OpenAlexW2769212127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.